Healthcare Decliners: Signal Genetics, Inc. (NASDAQ:SGNL), BG Medicine, Inc. (NASDAQ:BGMD), Cellular Biomedicine Group Inc. (NASDAQ:CBMG), Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), Connecture, Inc. (NASDAQ:CNXR)

Signal Genetics, Inc. (NASDAQ:SGNL) belongs to Healthcare sector. Its weekly performance is -27.73%. On last trading day company shares ended up $1.85. Signal Genetics, Inc. (NASDAQ:SGNL) distance from 50-day simple moving average (SMA50) is 6.04%. On 30 June, Signal Genetics, Inc. (NASDAQ:SGNL) announced the signing of a Master Service Agreement (MSA) with a leading pharmaceutical company. Under the MSA, Signal’s proprietary MyPRS(R) genetic test will be run across multiple clinical trials in connection with the development of novel treatments for patients with multiple myeloma.

BG Medicine, Inc. (NASDAQ:BGMD) shares fell -8.50% in last trading session and ended the day at $1.40. BGMD Gross Margin is 64.00% and its return on assets is -139.80%. BG Medicine, Inc. (NASDAQ:BGMD) quarterly performance is -57.32%. BG Medicine, Inc. (NASDAQ:BGMD) announced the effectiveness of a one-for-four reverse stock split of its common stock. The reverse stock split took effect at 5:00 pm Eastern Time on July 8, 2015 and the Company’s common stock open for trading on the NASDAQ Capital Market on July 9, 2015 on a post-split basis.

On 13 July, Cellular Biomedicine Group Inc. (NASDAQ:CBMG) shares fell -6.17% and was closed at $27.96. CBMG EPS growth in last 5 year was -20.20%. Cellular Biomedicine Group Inc. (NASDAQ:CBMG) year to date (YTD) performance is 116.58%. On 8 July, Cellular Biomedicine Group Inc. (NASDAQ:CBMG) announced the appointment of Alan List, MD as Chair of the Scientific Advisory Board. Dr. List will lead the board’s efforts to provide guidance and insight to advance CBMG’s multiple ongoing research programs and pipeline of therapies targeting unmet needs in the treatment of degenerative and cancerous diseases.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) ended the last trading day at $12.95. Company weekly volatility is calculated as 13.65% and price to cash ratio as 7.75. Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) showed a weekly performance of -5.06%. On 6 July, Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) announced that CAT-1004 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD). CAT-1004 is designed to inhibit activated NF-kB, which has the potential to reduce muscle inflammation and degeneration, and promote muscle regeneration for patients with DMD regardless of the underlying mutation.

Connecture, Inc. (NASDAQ:CNXR) shares fell -5.45% in last trading session and ended the day at $10.94. CNXR Gross Margin is 42.60% and its return on assets is -13.00%. Connecture, Inc. (NASDAQ:CNXR) quarterly performance is -5.03%. Connecture, Inc. (NASDAQ:CNXR), announced that executives from the company presented the second webinar in a two-part series on the 2016 Medicare Annual Enrollment Period, or AEP. Part two of the series occured on Thursday, July 9, 2015 at 12 p.m. CDT / 1:00 p.m. EDT.

Leave a Reply

Your email address will not be published. Required fields are marked *